Asset profile
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unm…
Newest first.
Tvardi Announces TTI-101 Phase 1b/2 HCC Topline Data Expected Early Q1 2027
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT05671835 | Phase 2 | Completed | Aug 14, 2025 | 100 | 28 of 28 sites in the United States |
| NCT05668949 | Phase 1/2 | Withdrawn | Sep 23, 2025 | 0 | |
| NCT05440708 | Phase 1/2 | Recruiting | May 25, 2027 | 193 | 21 of 21 sites in the United States |
Other drugs and candidates from the same company tracked in this sector.